Vertex eyes controllable genetic drugs with $1.3bn Obsidian allianceVertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Share XVertex eyes controllable genetic drugs with $1.3bn Obsidian alliancehttps://pharmaphorum.com/news/vertex-eyes-controllable-genetic-drugs-with-1-3bn-obsidian-alliance/
FDA fast tracks type 1 diabetes cell therapy from VertexVertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and Share XFDA fast tracks type 1 diabetes cell therapy from Vertexhttps://pharmaphorum.com/news/vertex-claims-fda-fast-track-status-for-diabetes-cell-therapy/
ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordersA gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta Share XASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordershttps://pharmaphorum.com/news/ash-crispr-vertex-ctx001-hits-the-mark-in-red-cell-disorders/
Vertex gets EU okay to treat younger cystic fibrosis patientsA new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children Share XVertex gets EU okay to treat younger cystic fibrosis patientshttps://pharmaphorum.com/news/vertex-gets-eu-okay-to-treat-younger-cystic-fibrosis-patients/
Vertex Pharma’s vision for reimbursement innovationAs regional vice president for Northern Europe & Australia, Simon Lem led the digital launch of Vertex Pharma’s Share XVertex Pharma’s vision for reimbursement innovationhttps://pharmaphorum.com/views-analysis-market-access/vertex-pharmas-vision-for-reimbursement-innovation/
Moderna broadens R&D scope with Vertex, Chiesi alliancesAll eyes may be on Moderna’s COVID-19 vaccine at the moment, but the US biotech hasn’t been idle Share XModerna broadens R&D scope with Vertex, Chiesi allianceshttps://pharmaphorum.com/news/moderna-broadens-rd-scope-with-vertex-chiesi-alliances/
Celebrations as NHS England agrees deal for Vertex’ cystic fibrosis tripleNHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after Share XCelebrations as NHS England agrees deal for Vertex’ cystic fibrosis triplehttps://pharmaphorum.com/news/celebrations-as-nhs-england-agrees-deal-for-vertex-cystic-fibrosis-triple/
As CHMP backs Vertex’ CF triple, campaigners plead for speedy UK dealCystic fibrosis patient groups in the UK are celebrating a recommendation by the EMA’s human medicines committee to Share XAs CHMP backs Vertex’ CF triple, campaigners plead for speedy UK dealhttps://pharmaphorum.com/news/as-chmp-backs-vertex-cf-triple-campaigners-plead-for-speedy-uk-deal/
CRISPR trials yield encouraging data in blood disordersData on the first two patients to be treated with a CRISPR-based drug for the blood disorders beta Share XCRISPR trials yield encouraging data in blood disordershttps://pharmaphorum.com/news/crispr-trials-yield-encouraging-data-in-blood-disorders/
